Integer Holdings Corporation (NYSE:ITGR) Receives $98.38 Average PT from Analysts

Shares of Integer Holdings Corporation (NYSE:ITGR) have been given an average recommendation of “Hold” by the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $98.3750.

ITGR has been the topic of a number of recent analyst reports. Bank of America lowered shares of Integer from a “buy” rating to a “neutral” rating and set a $87.00 price target on the stock. in a research report on Friday, October 24th. Raymond James Financial reiterated an “outperform” rating and issued a $95.00 target price (down previously from $143.00) on shares of Integer in a research note on Friday, October 24th. Argus lowered Integer from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $80.00 price target (down from $132.00) on shares of Integer in a report on Friday, October 24th. Finally, Piper Sandler cut their price objective on Integer from $155.00 to $82.00 and set an “overweight” rating for the company in a research report on Friday, October 24th.

Integer News Roundup

Here are the key news stories impacting Integer this week:

• Neutral Sentiment: Integer priced an $875 million notes offering — this is material for capital structure (could fund growth or refinancing and will increase interest-bearing debt). Investors should watch use of proceeds and any change to leverage/interest expense. Integer Holdings prices $875M notes offering
• Negative Sentiment: Multiple law firms have filed or announced securities‑class action lawsuits and are soliciting lead plaintiffs for the period July 25, 2024–Oct 22, 2025, citing alleged misstatements and a large prior stock drop; firms are urging investors to file before a Feb. 9 lead‑plaintiff deadline. Litigation exposure, potential damages, legal costs and management distraction are the primary drivers pressuring the stock. ITGR Deadline: ITGR Investors Have Opportunity to Lead Integer Holdings Corporation Securities Fraud Lawsuit

Integer Stock Down 1.3%

Shares of NYSE ITGR opened at $85.70 on Friday. Integer has a 52-week low of $62.00 and a 52-week high of $144.76. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.45 and a current ratio of 3.71. The business has a fifty day moving average of $78.74 and a two-hundred day moving average of $90.32. The stock has a market cap of $3.00 billion, a PE ratio of 35.86, a PEG ratio of 0.80 and a beta of 0.77.

Integer announced that its Board of Directors has authorized a share buyback plan on Tuesday, November 4th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the medical equipment provider to purchase up to 8.3% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other Integer news, VP Tommy P. Thomas sold 884 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $70.15, for a total transaction of $62,012.60. Following the sale, the vice president owned 3,596 shares of the company’s stock, valued at $252,259.40. This represents a 19.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Diron Smith bought 1,116 shares of the company’s stock in a transaction on Friday, November 7th. The stock was bought at an average cost of $67.19 per share, with a total value of $74,984.04. Following the completion of the purchase, the executive vice president owned 7,698 shares of the company’s stock, valued at approximately $517,228.62. The trade was a 16.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 2.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Tudor Investment Corp ET AL raised its position in shares of Integer by 50,787.5% during the third quarter. Tudor Investment Corp ET AL now owns 29,500,000 shares of the medical equipment provider’s stock worth $28,606,000 after acquiring an additional 29,442,029 shares during the last quarter. Vanguard Group Inc. increased its position in Integer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 3,886,150 shares of the medical equipment provider’s stock worth $304,791,000 after purchasing an additional 14,465 shares during the period. Dimensional Fund Advisors LP raised its holdings in Integer by 4.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,410,480 shares of the medical equipment provider’s stock worth $145,738,000 after purchasing an additional 65,865 shares during the last quarter. State Street Corp raised its holdings in Integer by 1.0% during the 2nd quarter. State Street Corp now owns 1,326,050 shares of the medical equipment provider’s stock worth $163,064,000 after purchasing an additional 13,540 shares during the last quarter. Finally, Viking Global Investors LP lifted its position in Integer by 9.1% during the 2nd quarter. Viking Global Investors LP now owns 1,283,965 shares of the medical equipment provider’s stock valued at $157,889,000 after purchasing an additional 106,692 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.